These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 10853928

  • 1. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
    Centofanti M, Manni G, Gregori D, Cocco F, Lorenzano D, Bucci MG.
    Graefes Arch Clin Exp Ophthalmol; 2000 Apr; 238(4):302-5. PubMed ID: 10853928
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC, Sharpe ED, Day DG, Kolker AE, Konstas AG, Lee WH, Rieser JC, Chopra H, Holmes KT.
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
    Simmons ST, Alphagan/Trusopt Study Group.
    Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
    Stewart WC, Sharpe ED, Harbin TS, Pastor SA, Day DG, Holmes KT, Stewart JA.
    Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
    [Abstract] [Full Text] [Related]

  • 6. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I.
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [Abstract] [Full Text] [Related]

  • 7. The short-term IOP-lowering effect of brimonidine 0.2% and dorzolomide 2% combination in primary open-angle glaucoma.
    Ermis SS, Ozturk F, Inan UU.
    Acta Ophthalmol Scand; 2002 Dec; 80(6):632-4. PubMed ID: 12485285
    [Abstract] [Full Text] [Related]

  • 8. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS.
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM, Tanna AP, Gross RL, Chuang AZ, Baker L, Reynolds A, Prager TC, Additivity Study Group.
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [Abstract] [Full Text] [Related]

  • 10. [Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers].
    Carrasco Font C, Arias Puente A, García Sáenz MC, Villarejo Díaz-Maroto I.
    Arch Soc Esp Oftalmol; 2004 Apr; 79(4):163-8. PubMed ID: 15124072
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE, Ghosh K, Gieser DK, Adamsons IA.
    Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group.
    Boyle JE, Ghosh K, Gieser DK, Adamsons IA.
    Ophthalmology; 1998 Oct; 105(10):1945-51. PubMed ID: 9787368
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A, Paczka JA, Jiménez-Román J, Hartleben C.
    BMC Ophthalmol; 2014 Dec 19; 14():161. PubMed ID: 25527295
    [Abstract] [Full Text] [Related]

  • 14. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN, Greff LJ, Johnson-Pratt LR, DeLucca PT, Polis AB, Kolodny AH, Fletcher CA, Cassel DA, Boyle DR, Skobieranda F.
    Ophthalmology; 2003 Mar 19; 110(3):615-24. PubMed ID: 12623832
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J.
    Eur J Ophthalmol; 2000 Mar 19; 10(3):198-204. PubMed ID: 11071026
    [Abstract] [Full Text] [Related]

  • 16. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST, Earl ML, Alphagan/Xalatan Study Group.
    Ophthalmology; 2002 Feb 19; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [Abstract] [Full Text] [Related]

  • 17. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE, Lai J.
    Ophthalmology; 2009 Sep 19; 116(9):1719-24. PubMed ID: 19592108
    [Abstract] [Full Text] [Related]

  • 18. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP.
    Ophthalmology; 1998 Oct 19; 105(10):1960-7. PubMed ID: 9787370
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
    Lee DA, Gornbein JA.
    J Glaucoma; 2001 Jun 19; 10(3):220-6. PubMed ID: 11442187
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.